{"product_id":"carotid-plaque-rads-a-new-stroke-risk-classification-system-explained-for-patients","title":"Carotid Plaque-RADS: A New Stroke Risk Classification System, Explained for Patients","description":"\u003cp\u003eCarotid artery plaque (fatty buildup in the neck arteries) is a leading cause of stroke, yet doctors have lacked a single, standardized system for describing and scoring what they see on imaging scans. This paper introduces the Carotid Plaque-RADS (Reporting and Data System), a universal classification that grades plaque from 1 (no plaque at all) to 4 (complicated, high-risk plaque) using ultrasound, computed tomography, or magnetic resonance imaging. The system goes beyond the traditional measure of \"percent stenosis\" (how narrowed the artery is) and instead captures dangerous plaque features like intraplaque hemorrhage and fibrous cap rupture. Its goal is to improve communication between radiologists and clinicians, enable better research data sharing, and help identify which patients need aggressive medical therapy versus surgical or interventional treatments.\u003c\/p\u003e\n\n\u003ch1\u003eCarotid Plaque-RADS: A New Stroke Risk Classification System, Explained for Patients\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eWhy This Research Matters: Carotid Plaque and Stroke\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#rationale\"\u003eWhy a New Classification System Was Needed\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Plaque-RADS System Was Developed\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#overview\"\u003eThe Plaque-RADS Categories at a Glance\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#rads1\"\u003ePlaque-RADS 1: No Plaque (Normal Vessel Wall)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#rads2\"\u003ePlaque-RADS 2: Low-Risk Plaque\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#rads3\"\u003ePlaque-RADS 3: Moderate-Risk Plaque\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#rads4\"\u003ePlaque-RADS 4: High-Risk Complicated Plaque\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ancillary\"\u003eAncillary Features and Modifiers\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eCarotid Plaque-RADS is a new system that grades carotid plaque from 1 (no plaque) to 4 (complicated).\u003c\/li\u003e\n\u003cli\u003eIt goes beyond percent stenosis by capturing dangerous plaque features like intraplaque hemorrhage and fibrous cap rupture.\u003c\/li\u003e\n\u003cli\u003eThe score can be assigned using ultrasound, CT, or MRI, but imaging modality should always be reported.\u003c\/li\u003e\n\u003cli\u003ePlaque-RADS aims to standardize reporting, improve research collaboration, and guide personalized stroke prevention.\u003c\/li\u003e\n\u003cli\u003eDeveloped by expert consensus, it has not yet been validated in prospective studies to confirm improved patient outcomes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eWhy This Research Matters: Carotid Plaque and Stroke\u003c\/h2\u003e\n\n\u003cp\u003eCarotid artery atherosclerosis (hardening and thickening of the artery walls due to plaque buildup) is highly prevalent in the general population. It is also a well-established risk factor for acute ischemic stroke, the type of stroke caused by a blocked blood vessel. Thousands of patients each year experience strokes that originate from plaque in the carotid arteries, the two large blood vessels in the neck that supply blood to the brain.\u003c\/p\u003e\n\n\u003cp\u003eFor years, doctors have relied primarily on one number when evaluating carotid artery disease: the degree of stenosis, or the percentage of artery narrowing, often measured using the NASCET (North American Symptomatic Carotid Endarterectomy Trial) criteria. But medical research has shown that the \u003cem\u003echaracteristics of the plaque itself\u003c\/em\u003e matter just as much as how narrow the artery is. Some plaques are \"vulnerable\" (unstable and prone to causing strokes), while others are stable and harmless.\u003c\/p\u003e\n\n\u003cp\u003eAlthough the morphological characteristics (physical features) of vulnerable plaques are well recognized, there has been a lack of consensus in reporting and interpreting carotid plaque features. Different hospitals use different terms, different measurement standards, and different reporting formats, which makes it difficult to compare studies, share data, and provide consistent patient care.\u003c\/p\u003e\n\n\u003cp\u003eThe 2017 European Society of Cardiology clinical practice guidelines recognized this problem. They recommend evaluating the presence of plaque imaging characteristics that may indicate an increased risk of ipsilateral stroke (stroke on the same side as the plaque), \u003cem\u003ein addition to\u003c\/em\u003e the degree of carotid stenosis in asymptomatic individuals. These features include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIntraplaque hemorrhage (IPH)\u003c\/strong\u003e — bleeding inside the plaque itself\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLipid-rich necrotic core (LRNC)\u003c\/strong\u003e — a collection of dead tissue and cholesterol within the plaque\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLarge or echolucent plaques\u003c\/strong\u003e — plaques that appear dark on ultrasound, indicating soft, unstable material\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIncreased juxtaluminal black (hypoechoic) areas\u003c\/strong\u003e — dark regions near the artery opening on ultrasound\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe European Society for Vascular Surgery clinical practice guidelines similarly emphasize the importance of plaque vulnerability assessment.\u003c\/p\u003e\n\n\u003ch2 id=\"rationale\"\u003eWhy a New Classification System Was Needed\u003c\/h2\u003e\n\n\u003cp\u003eWhile several scoring systems exist for individual imaging methods, there has been no universal classification that works across all modalities. Some examples of existing systems include the American Heart Association (AHA) lesion types, the modified AHA lesion types for MRI, and the carotid plaque score for ultrasound. These systems are useful, but each is tied to a particular imaging technology.\u003c\/p\u003e\n\n\u003cp\u003eThe lack of a common system has real consequences. In most clinical reports of computed tomography angiography (CTA), doctors mention the degree of carotid stenosis, but specific plaque features are accounted for in only a minority of cases. This may be due to gaps in knowledge about high-risk plaque features, their associated stroke risk, and potential therapeutic consequences.\u003c\/p\u003e\n\n\u003cp\u003eThe proposed Plaque-RADS score aims to create an intuitive, accurate, reliable, and standardized scoring system that can be used with various imaging modalities. It provides risk estimates for first-time or recurrent large artery cerebrovascular events (stroke or transient ischemic attack, often called a \"mini-stroke\").\u003c\/p\u003e\n\n\u003cp\u003ePrevious standardized reporting systems have proven their value in other areas of medicine. The Lung-RADS score standardized lung cancer screening. The BI-RADS system did the same for breast imaging, PI-RADS for prostate, LI-RADS for liver, and CAD-RADS for coronary artery imaging. In each case, standardized reporting improved communication, reduced differences in terminology, and facilitated the exchange of clear, systematic information between imaging physicians, referring doctors, and researchers.\u003c\/p\u003e\n\n\u003cp\u003eThe introduction of Plaque-RADS offers three major benefits:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStandardization:\u003c\/strong\u003e It levels the differences across institutions regarding terminology and patient evaluation criteria, serving as a reference format in everyday clinical practice.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eResearch facilitation:\u003c\/strong\u003e It allows researchers across different institutions to collect information in a more homogeneous, synergistic way. Over time, stratified prognostic data (outcome data grouped by category) could be collected for each Plaque-RADS category, helping clinicians design agreed-upon treatment flowcharts.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eParadigm shift:\u003c\/strong\u003e It draws attention to imaging findings that represent plaque morphology and composition, going beyond the mere degree of stenosis.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Plaque-RADS System Was Developed\u003c\/h2\u003e\n\n\u003cp\u003eA panel of experts in radiology, vascular surgery, neurology, cardiology, and pathology recognized the necessity of developing a classification system for carotid plaque and its defining characteristics. Using a multimodality analysis approach (reviewing evidence from ultrasound, CT, and MRI studies), the Plaque-RADS categories were established through consensus, drawing on existing published reports.\u003c\/p\u003e\n\n\u003cp\u003eThe score is applied on a per-vessel basis (each carotid artery is scored separately) and can be established using ultrasound, computed tomography angiography, or magnetic resonance imaging. The authors note that not all imaging modalities are currently equally suited to identify each category, so the modality used to obtain the score should always be provided alongside the score itself.\u003c\/p\u003e\n\n\u003cp\u003eCategories range from Plaque-RADS 1 (complete absence of atherosclerosis) to Plaque-RADS 4 (complicated plaque, meaning plaque with dangerous features like bleeding, rupture, or blood clot). Further subspecifications (a, b, c) can be provided for Plaque-RADS categories 3 and 4, and these represent the clinically most relevant finding per vessel.\u003c\/p\u003e\n\n\u003cp\u003eThe paper includes a step-by-step flowchart (Figure 1) and a Central Illustration providing a schematic overview of the scoring system, along with accompanying visual examples from ultrasound, CT, MRI, and histology (microscopic tissue examination) for each category.\u003c\/p\u003e\n\n\u003ch2 id=\"overview\"\u003eThe Plaque-RADS Categories at a Glance\u003c\/h2\u003e\n\n\u003cp\u003eThe table below summarizes the Plaque-RADS categories, their imaging findings, and the attributable risk (the risk directly linked to each plaque type) of experiencing an ipsilateral cerebrovascular event (a stroke or mini-stroke on the same side as the plaque):\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlaque-RADS 1:\u003c\/strong\u003e Normal vessel wall. Attributable risk: absent.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlaque-RADS 2:\u003c\/strong\u003e Maximum wall thickness (MWT) less than 3 mm. Attributable risk: low.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlaque-RADS 3:\u003c\/strong\u003e MWT of 3 mm or more, or healed ulcerated plaque. Attributable risk: moderate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlaque-RADS 3a:\u003c\/strong\u003e Lipid-rich necrotic core (LRNC) with intact thick fibrous cap (FC), MWT of 3 mm or more. Attributable risk: moderate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlaque-RADS 3b:\u003c\/strong\u003e LRNC with thin FC, MWT of 3 mm or more. Attributable risk: moderate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlaque-RADS 3c:\u003c\/strong\u003e Healed ulcerated plaque. Attributable risk: moderate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlaque-RADS 4:\u003c\/strong\u003e Complicated plaque, irrespective of wall thickness. Attributable risk: high.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlaque-RADS 4a:\u003c\/strong\u003e Intraplaque hemorrhage (IPH). Attributable risk: high.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlaque-RADS 4b:\u003c\/strong\u003e Ruptured fibrous cap. Attributable risk: high.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlaque-RADS 4c:\u003c\/strong\u003e Intraluminal thrombus (blood clot on the surface of the plaque). Attributable risk: high.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAncillary features that can be noted alongside the score include inflammation, neovascularization (growth of new, fragile blood vessels within the plaque), positive plaque remodeling (the artery expands outward to accommodate the plaque), plaque burden, progression of stenosis, and calcifications. Modifiers include \"L\" for limited diagnostic study, \"Stent\" if a stent is present, and \"CEA\" if the patient has had a previous carotid endarterectomy (surgical removal of plaque).\u003c\/p\u003e\n\n\u003ch2 id=\"rads1\"\u003ePlaque-RADS 1: No Plaque (Normal Vessel Wall)\u003c\/h2\u003e\n\n\u003cp\u003eThis category represents the normal vessel wall with no evidence of localized atherosclerotic plaque. On ultrasound, the vessel wall appears homogeneous and thin. On CT, the wall of the common carotid artery and its bifurcation (the point where it splits into internal and external branches) appears regular. On MRI, the wall likewise appears regular. Histology (microscopic examination) shows a normal vessel wall with mild intimal thickening (minor thickening of the innermost layer) that cannot be seen with current living-patient imaging technologies.\u003c\/p\u003e\n\n\u003cp\u003ePopulation-based cohort studies including the Rotterdam Study, the Tromsø Study, and the MESA (Multi-Ethnic Study of Atherosclerosis) study have shown that patients without carotid plaque are not at risk of atherosclerosis-related cardiovascular (heart and blood vessel) or cerebrovascular (brain blood vessel) events. Vessels in this category correspond to AHA lesion-type I\/II plaques, which are the earliest, minimal changes in the artery wall.\u003c\/p\u003e\n\n\u003ch2 id=\"rads2\"\u003ePlaque-RADS 2: Low-Risk Plaque\u003c\/h2\u003e\n\n\u003cp\u003eThis category is defined by an eccentric plaque (plaque that is thicker on one side of the artery wall than the other) with a maximum wall thickness (MWT) of less than 3 mm, and the absence of complicated plaque features such as intraplaque hemorrhage, fibrous cap rupture, and intraluminal thrombus.\u003c\/p\u003e\n\n\u003cp\u003ePlaques in this category may consist mainly of fibrous tissue (scar-like connective tissue), small lipid pools, a small lipid-rich necrotic core, calcifications, or a combination of these tissue types. These plaque features are hallmarks of relatively stable plaques, although they are also potential precursors of more advanced lesions.\u003c\/p\u003e\n\n\u003cp\u003eThe presence of these features results in an increase in wall thickness that has been shown to be associated with increased cerebrovascular and cardiovascular risk — but less than the risk associated with complicated plaque features. In this regard, total plaque thickness, as determined by ultrasound, has been shown to improve the prediction of future atherosclerotic cardiovascular events over and above that provided by traditional risk factors alone (such as blood pressure, cholesterol, smoking, and diabetes).\u003c\/p\u003e\n\n\u003cp\u003eThe risk of Plaque-RADS 2 lesions is higher than Plaque-RADS 1 lesions, but it is still relatively low. This category contains plaques corresponding to AHA lesion types III, IV\/V (small), VII, and VIII. The rationale for choosing a cutoff of MWT below 3 mm is discussed in the paper's Supplemental Methods, but the key point is that wall thickness under 3 mm carries low risk in the authors' consensus view.\u003c\/p\u003e\n\n\u003ch2 id=\"rads3\"\u003ePlaque-RADS 3: Moderate-Risk Plaque\u003c\/h2\u003e\n\n\u003cp\u003eThis category represents a carotid plaque with an MWT of 3 mm or more, which may consist of a moderate to large lipid-rich necrotic core (LRNC), calcifications, healed ulcerations, and fibrous tissue. Complicated plaque features — such as intraplaque hemorrhage, thrombus (blood clot), and plaque rupture — are absent.\u003c\/p\u003e\n\n\u003cp\u003eFurther subclassification (3a, 3b, 3c) may be undertaken with dedicated imaging. This category contains plaques corresponding to AHA lesion types IV\/V, VII, and VIII (advanced but not yet \"complicated\" lesions).\u003c\/p\u003e\n\n\u003ch3\u003ePlaque-RADS 3a: LRNC with Thick Fibrous Cap\u003c\/h3\u003e\n\n\u003cp\u003eThis subcategory represents a carotid plaque with a moderate to large lipid-rich necrotic core (LRNC — a collection of dead cells and cholesterol inside the plaque), a thick fibrous cap (FC — the layer of connective tissue separating the core from the blood flow), and an MWT of 3 mm or more, in the absence of complicated plaque features.\u003c\/p\u003e\n\n\u003cp\u003eCurrently, data on the risk of LRNC is limited. However, a meta-analysis by Gupta et al. (a statistical combination of multiple studies) showed an increased risk for future ipsilateral cerebrovascular events when LRNC is present, with a hazard ratio (HR) of 3.00 (95% CI: 1.511–5.945; P = 0.002). In plain language: patients with an LRNC had 3 times the risk of a future stroke on the same side as the plaque compared to patients without this feature, and this result is statistically significant (the P value of 0.002 means there is only a 0.2% chance the finding occurred by random luck). Besides an increased downstream cerebrovascular risk, the presence of an LRNC is also associated with an increase in cardiovascular risk (heart attacks and related events).\u003c\/p\u003e\n\n\u003ch3\u003ePlaque-RADS 3b: LRNC with Thin Fibrous Cap\u003c\/h3\u003e\n\n\u003cp\u003eThis subcategory contains carotid plaque with an MWT of 3 mm or more, with a moderate to large LRNC and a thin but intact fibrous cap.\u003c\/p\u003e\n\n\u003cp\u003eIt must be emphasized that the capability of contemporary imaging to accurately assess thin fibrous caps lacks evidence. Thus, for assigning a score of 3b in the Plaque-RADS classification system, the thin FC may be either directly visualized (if the spatial resolution of the modality in use allows that) or inferred by the presence of an LRNC without visualization of a thick and intact FC. Most importantly, what distinguishes this class from the higher-risk class 4 is the absence of complicated plaque features.\u003c\/p\u003e\n\n\u003cp\u003eRegarding FC integrity, several studies have emphasized its determinant role in plaque stability. A thick FC is associated with a low risk of plaque rupture, whereas the risk of rupture increases for a thin FC. This makes the fibrous cap thickness a critical factor in assessing whether a plaque is likely to cause problems.\u003c\/p\u003e\n\n\u003ch3\u003ePlaque-RADS 3c: Healed Ulcerated Plaque\u003c\/h3\u003e\n\n\u003cp\u003eThe defining feature of this category is plaque ulceration (a crater or cavity on the plaque surface) regardless of plaque thickness, in the absence of intraplaque hemorrhage, fibrous cap disruption, or intraluminal thrombus.\u003c\/p\u003e\n\n\u003cp\u003eIn the Plaque-RADS classification system, the term \"ulceration\" in the context of score 3c must be understood as ulceration \u003cem\u003enot\u003c\/em\u003e associated with the presence of IPH (which would be score 4a), visible FC disruption (score 4b), or intraluminal thrombus (score 4c). Rather, the term ulceration in this context refers to a surface cavity most likely secondary to previous extrusion of atheromatous material (plaque contents that have been released), in the context of a healed or healing process.\u003c\/p\u003e\n\n\u003ch2 id=\"rads4\"\u003ePlaque-RADS 4: High-Risk Complicated Plaque\u003c\/h2\u003e\n\n\u003cp\u003eThis category represents complicated plaque — plaque that has developed dangerous features — irrespective of wall thickness. Subclasses 4a, 4b, and 4c correspond to intraplaque hemorrhage, ruptured fibrous cap, and intraluminal thrombus, respectively. These subclasses may provide important information in future studies to better understand statistical correlations between such specific entities and clinical events. This category contains plaques corresponding to AHA lesion-type VI (complicated lesions).\u003c\/p\u003e\n\n\u003ch3\u003ePlaque-RADS 4a: Intraplaque Hemorrhage (IPH)\u003c\/h3\u003e\n\n\u003cp\u003eThe defining feature of this category is intraplaque hemorrhage (IPH) — bleeding inside the plaque itself. IPH is one of the most powerful predictors of stroke. In the CAPIAS (Carotid Plaque Imaging in Acute Stroke) study, IPH was the most common feature of complicated plaques and was present in 89% of all complicated plaques located on the same side as an acute ischemic stroke. In other words, nearly 9 out of 10 complicated plaques that caused a stroke contained bleeding within the plaque.\u003c\/p\u003e\n\n\u003cp\u003eIn the recent prospective PARISK (Plaque At RISK) study of 244 patients with a recent symptomatic mild-to-moderate carotid stenosis (artery narrowing of less than 70%, accompanied by symptoms), researchers followed patients over a mean period to evaluate which plaque features best predicted recurrent events (the full results of this study are detailed in the original paper's ongoing references).\u003c\/p\u003e\n\n\u003ch3\u003ePlaque-RADS 4b: Ruptured Fibrous Cap\u003c\/h3\u003e\n\n\u003cp\u003eThe defining feature of this category is a ruptured fibrous cap — the thin protective layer covering the plaque core has torn open, exposing the dangerous inner contents to the bloodstream. A ruptured FC is the mechanism by which plaque contents trigger blood clotting and downstream blockage of brain blood vessels. When the fibrous cap ruptures, the body's clotting system activates at the site, which can lead to stroke.\u003c\/p\u003e\n\n\u003ch3\u003ePlaque-RADS 4c: Intraluminal Thrombus\u003c\/h3\u003e\n\n\u003cp\u003eThe defining feature of this category is intraluminal thrombus — a blood clot that has formed inside the artery lumen (the open channel where blood flows), attached to the surface of the plaque. An intraluminal thrombus is an extremely dangerous finding because pieces of the clot can break off, travel downstream, and block smaller brain blood vessels, causing stroke. This finding represents the end stage of plaque complication and carries the highest immediate risk.\u003c\/p\u003e\n\n\u003ch2 id=\"ancillary\"\u003eAncillary Features and Modifiers\u003c\/h2\u003e\n\n\u003cp\u003eThe Plaque-RADS categories may be supplemented by \"ancillary features\" of carotid plaque vulnerability. These are additional imaging findings that may provide extra risk information but are not part of the core score. They include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlaque inflammation\u003c\/strong\u003e — inflammatory activity within the plaque, detectable with advanced imaging techniques like FDG-PET\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNeovascularization\u003c\/strong\u003e — the growth of new, fragile blood vessels into the plaque, which can be a source of bleeding\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePositive carotid artery remodeling\u003c\/strong\u003e — the artery wall expands outward to accommodate the plaque, which can hide the true plaque burden when only stenosis is measured\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlaque burden\u003c\/strong\u003e — the total volume or amount of plaque present\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProgression of stenosis\u003c\/strong\u003e — worsening of artery narrowing over time\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCarotid plaque calcifications\u003c\/strong\u003e — mineral deposits within the plaque, which can affect stability in complex ways\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eModifiers that should be recorded alongside the score include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\"L\"\u003c\/strong\u003e — limited diagnostic study (the imaging was not fully adequate for confident classification)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\"Stent\"\u003c\/strong\u003e — the carotid artery contains a stent from prior treatment\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\"CEA\"\u003c\/strong\u003e — the patient has had a previous carotid endarterectomy (surgical removal of plaque from the artery)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe Plaque-RADS system has the potential to help in the precise identification of patients who may benefit from exclusive medical intervention (such as aggressive cholesterol-lowering therapy with statins, antiplatelet medications, and blood pressure control) and those who require alternative treatments (such as carotid endarterectomy or carotid artery stenting). This is a significant step toward personalized medicine for stroke prevention.\u003c\/p\u003e\n\n\u003cp\u003eFor patients, this means that future imaging reports may include a Plaque-RADS score that tells your doctor not just how narrowed your carotid artery is, but \u003cem\u003ehow dangerous your plaque is\u003c\/em\u003e. A patient with a high-degree stenosis but a stable, low-risk plaque (Plaque-RADS 2) might be managed differently than a patient with the same stenosis but a complicated, high-risk plaque (Plaque-RADS 4a with intraplaque hemorrhage).\u003c\/p\u003e\n\n\u003cp\u003eThe system also promises to enhance communication between radiologists, referring clinicians, and scientists. A standardized lexicon (shared vocabulary) and structured reporting format means that a radiologist in one hospital can describe a plaque in exactly the same terms as a radiologist in another hospital — or another country. This is essential for large-scale research and for ensuring that patients get consistent, evidence-based care regardless of where they are treated.\u003c\/p\u003e\n\n\u003cp\u003eImportantly, the authors note that the imaging modality used (ultrasound, CT, or MRI) should always be reported alongside the Plaque-RADS score, because not all modalities are equally capable of detecting all plaque features. For example, CT cannot reliably assess the fibrous cap status, while MRI is the gold standard for detecting intraplaque hemorrhage.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\n\u003cp\u003eSeveral limitations should be kept in mind when interpreting this work.\u003c\/p\u003e\n\n\u003cp\u003eFirst, the Plaque-RADS classification was developed through expert consensus rather than through a prospective validation study. While the categories are grounded in existing published evidence, the system itself has not yet been tested prospectively to confirm that it improves patient outcomes compared with current practice.\u003c\/p\u003e\n\n\u003cp\u003eSecond, not all imaging modalities are currently equally suited to identify each category. For example, the capability of contemporary imaging to accurately assess thin fibrous caps lacks evidence. This means that some categories are easier to assign with certain modalities than others, and the authors emphasize that the modality should always be provided.\u003c\/p\u003e\n\n\u003cp\u003eThird, data on the risk associated with some individual features — such as the lipid-rich necrotic core — is limited. While the meta-analysis by Gupta et al. showed a hazard ratio of 3.00 (95% CI: 1.511–5.945; P = 0.002) for future cerebrovascular events, this is based on pooling of existing studies with their own limitations.\u003c\/p\u003e\n\n\u003cp\u003eFourth, the authors note that the system draws on existing published reports, and some categories (particularly the subclasses) will need further study to confirm their clinical utility in predicting events.\u003c\/p\u003e\n\n\u003cp\u003eFinally, future work will need to determine how the Plaque-RADS score should integrate with other risk factors and biomarkers in clinical decision-making. The system is designed to be a structured reporting tool, not a standalone treatment algorithm, and its ultimate value depends on how it is used alongside the full clinical picture.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is Carotid Plaque-RADS and what does it do?\u003c\/h3\u003e\n\u003cp\u003eCarotid Plaque-RADS is a new standardized classification system for carotid artery plaque seen on imaging. It grades plaque from 1 (no plaque) to 4 (complicated, high-risk plaque) using ultrasound, CT, or MRI. It helps doctors communicate clearly about stroke risk and decide which patients need more aggressive treatment.\u003c\/p\u003e\n\u003ch3\u003eHow is my carotid plaque grade determined?\u003c\/h3\u003e\n\u003cp\u003eDoctors assign a Plaque-RADS grade by reviewing your carotid artery imaging. They look at maximum wall thickness and dangerous features such as intraplaque hemorrhage, fibrous cap rupture, or blood clot. The imaging modality used is noted because not all methods detect every feature equally well.\u003c\/p\u003e\n\u003ch3\u003eWhat does a Plaque-RADS 4 score mean?\u003c\/h3\u003e\n\u003cp\u003ePlaque-RADS 4 means you have complicated, high-risk plaque, regardless of artery narrowing. It includes intraplaque hemorrhage (4a), ruptured fibrous cap (4b), or intraluminal thrombus (4c). These features carry a high risk of stroke on the same side as the plaque. Your doctor will use this with your full clinical picture.\u003c\/p\u003e\n\u003ch3\u003eDoes Plaque-RADS replace measuring how narrowed my carotid artery is?\u003c\/h3\u003e\n\u003cp\u003eNo. Plaque-RADS goes beyond the traditional percent stenosis measurement. It adds information about plaque composition and dangerous features. Doctors still consider artery narrowing, but Plaque-RADS helps determine how dangerous the plaque is, not just how narrow the artery has become.\u003c\/p\u003e\n\u003ch3\u003eHow does the Plaque-RADS score affect my treatment options?\u003c\/h3\u003e\n\u003cp\u003eA higher Plaque-RADS score may lead to more aggressive medical therapy, such as intensive cholesterol-lowering medication, antiplatelet drugs, and blood pressure control. Patients with complicated high-risk plaque (Plaque-RADS 4) might be considered for procedures like carotid endarterectomy or stenting. The score helps personalize stroke prevention based on plaque danger.\u003c\/p\u003e\n\u003ch3\u003eShould I get a second opinion before having carotid stenting or endarterectomy based on a Plaque-RADS score of 4?\u003c\/h3\u003e\n\u003cp\u003eA carotid Plaque-RADS score of 4 indicates complicated, high-risk plaque such as intraplaque hemorrhage, fibrous cap rupture, or blood clot on the plaque. These features carry high attributable risk of stroke. Because the score helps determine whether a patient needs aggressive medical therapy versus carotid endarterectomy or stenting, a second opinion that re-reviews the original imaging may be valuable. Scores can differ by modality; MRI is the gold standard for detecting intraplaque hemorrhage. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Carotid Plaque-RADS A Novel Stroke Risk Classification System\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Luca Saba, MD; Riccardo Cau, MD; Alessandro Murgia, MD; Andrew N. Nicolaides, MS, DSC; Max Wintermark, MD; Mauricio Castillo, MD; Daniel Staub, MD; Stavros K. Kakkos, MD, PhD; Qi Yang, MD, PhD; Kosmas I. Paraskevas, MD; Chun Yuan, PhD; Myriam Edjlali, MD, PhD; Roberto Sanfilippo, MD; Jeroen Hendrikse, MD, PhD; Elias Johansson, MD; Mahmud Mossa-Basha, MD; Niranjan Balu, MD, PhD; Martin Dichgans, MD; David Saloner, PhD; Daniel Bos, MD, PhD; H. Rolf Jager, MD; Ross Naylor, MD; Gavino Faa, MD; Jasjit S. Suri, PhD; Justin Costello, MD; Dorothee P. Auer, MD; J. Scott McNally, MD, PhD; Leo H. Bonati, MD; Valentina Nardi, MD; Aad van der Lugt, MD; Maura Griffin, MSC, PhD; Bruce A. Wasserman, MD; M. Eline Kooi, PhD; Jonathan Gillard, MD; Giuseppe Lanzino, MD; Dimitri P. Mikhailidis, MD; Daniel M. Mandell, MD, PhD; John C. Benson, MD; Dianne H. K. van Dam-Nolen, MD; Anna Kopczak, MD; Jae W. Song, MD; Ajay Gupta, MD; J. Kevin DeMarco, MD; Seemant Chaturvedi, MD; Renu Virmani, MD; Thomas S. Hatsukami, MD; Martin Brown, MD; Alan R. Moody, MD; Peter Libby, MD; Andreas Schindler, MD; and Tobias Saam, MD (Drs. Schindler and Saam contributed equally as co-senior authors)\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e JACC: Cardiovascular Imaging, Volume 17, Issue 1, January 2024, pages 62–75. Published by Elsevier on behalf of the American College of Cardiology Foundation. DOI: https:\/\/doi.org\/10.1016\/j.jcmg.2023.09.005\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eManuscript history:\u003c\/strong\u003e Received July 14, 2023; revised manuscript received September 6, 2023; accepted September 12, 2023.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research published in JACC: Cardiovascular Imaging. This content is provided for educational purposes only and is not a substitute for professional medical advice. Patients with questions about carotid plaque or stroke risk should consult their healthcare provider.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47560935768220,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/it\/products\/carotid-plaque-rads-a-new-stroke-risk-classification-system-explained-for-patients","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}